Your session is about to expire
← Back to Search
Veliparib + Topotecan ± Carboplatin for Leukemia
Study Summary
This trial is studying the side effects and best dose of veliparib when given with topotecan hydrochloride and carboplatin in treating patients with relapsed or refractory acute leukemia, high-risk myelodysplasia, or aggressive myeloproliferative disorders.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2024 Phase 3 trial • 509 Patients • NCT02163694Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I have waited the required time since my last cancer treatment.My brain leukemia has been stable for over 3 months after treatment.I have chronic myelomonocytic leukemia.I can take care of myself and perform daily activities.I do not have an active blood clotting disorder.I do not have any ongoing infections that aren't under control.I have an infection, but it is under control.I have never had seizures.I have had few or no chemotherapy treatments before.I do not have active graft-versus-host disease.My cancer returned after it was initially gone with treatment.I have been diagnosed with aggressive myeloproliferative disease or acute myeloid leukemia.My blood disorder is in an aggressive, high-risk stage.I am HIV positive but not on antiretroviral therapy.I have never taken ABT-888.I am not receiving any other cancer treatments.I do not have any other severe illnesses.
- Group 1: Treatment (veliparib, topotecan hydrochloride, carboplatin)
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Are there any precedents of Veliparib being utilized in research?
"Veliparib was initially studied at Bristol Royal Hospital for Children in 2002 which led to the completion of 1517 clinical trials. Currently, 758 studies are actively recruiting patients and a large portion can be found in Rochester, Minnesota."
Are there any potential harm associated with the use of Veliparib?
"Because it is currently a Phase 1 trial, the safety of Veliparib was assessed as 1 – meaning that there is limited data available to support its efficacy and security."
What therapeutic applications is Veliparib typically utilized for?
"Veliparib is the preferred treatment for advanced thymoma and can be an effective intervention in managing various other medical conditions such as neuroendocrine carcinoma, testicular cancer, and advance directives."
How many participants has this clinical trial enrolled thus far?
"This medical trial is no longer actively enrolling participants. It was first posted on November 28th 2007 and the last update occurred on June 28th 2022. If you're searching for other studies, there are 3900 trials with patients seeking treatment for polycythemia vera, as well as 758 different studies currently recruiting people who may benefit from Veliparib."
Are there any available slots in this experimentation for fresh participants?
"This particular experiment is not enrolling participants at this juncture. It was initially posted on 28th November 2007 and the information was updated last on 28th June 2022. If you are in search of other trials, there are 3900 studies currently looking for polycythemia vera patients and 758 research projects searching for Veliparib volunteers."
Share this study with friends
Copy Link
Messenger